Hospira

As the hospital products business of Abbott Laboratories:

1930s

Discovery and launch of Pentothal® (sodium thiopental) CIII, one of the most widely used induction anesthetics in the world

1940s-1950s

Introduction of the first fully disposable intravenous (I.V.) administration set
Introduction of new protein solution for I.V. feeding

1970s

Discovery and launch of the company's first electronic drug delivery pump
Introduction of the company's first flexible I.V. container, decreasing the use of glass in the hospital

1980s

Discovery and launch of the world's first patient-controlled analgesia (PCA) device
Acquisition of high-tech critical care monitoring systems
Introduction of the ADD-Vantage® drug delivery system, helping decrease pharmacy preparation time and delivery time to patient

1990s

Expansion of generic acute-care injectables portfolio, helping to reduce the high cost of proprietary pharmaceuticals
Introduction of premixed solutions
Introduction of prefilled syringes to help reduce the potential for medication errors and increase convenience
Introduction of needleless products to improve healthcare worker safety

2000s

Introduction of Hospira MedNet® drug library software
Completion of industry-leading patient safety effort to affix unit-of-use bar codes to all of our more than 1,000 hospital injectable pharmaceuticals and I.V. solutions

As Hospira:

2000s

Launch of Hospira as independent company, publicly traded on the New York Stock Exchange (NYSE) under ticker symbol 'HSP'
Introduction of wireless Hospira MedNet drug library safety software
Launch of Hospira Foundation as philanthropic arm of Hospira, Inc.
Launch of LifeCare PCA® infusion system
Introduction of next-generation VisIV™ I.V. container; the first significantly advanced I.V. bag in 30 years
Acquisition of BresaGen biotechnology company
Launch of Symbiq® next-generation infusion system
Signing of strategic agreements with STADA and BIOCEUTICALS for a biosimilar product
Launch of iSecure™ proprietary syringe
Acquisition of Mayne Pharma Limited
Launch of Retacrit® (epoetin zeta), Hospira’s first biosimilar